Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tacrolimus Fujisawa.

Andrew T Gewirtz1, Shanthi V Sitaraman

  • 1Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, GA 30322, USA. agewirt@emory.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary

Tacrolimus, an immunosuppressant, is being evaluated for inflammatory bowel disease (IBD). This evaluation focuses on its development for treating IBD, building on its established use in organ transplantation and atopic dermatitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut segmented filamentous Bacteria impedes growth of B16F10 subcutaneous tumors via modulating T cell function.

Mucosal immunology·2026
Same author

Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.

Gut microbes·2026
Same author

Elevated Circulating Bile Acids Driven Erythrocyte Osmotic Resistance Marks Hepatobiliary Disease.

American journal of physiology. Gastrointestinal and liver physiology·2026
Same author

Maternal Aflatoxin Exposure, Birth Outcomes, and Infant Growth in Uganda.

The American journal of tropical medicine and hygiene·2026
Same author

Microbial metabolite Enterobactin impairs mitochondrial respiration and alleviates colitis.

Gut microbes·2026
Same author

Wheat fiber mitigates colitis via non-SCFA microbial metabolite-trained intestinal macrophages.

Science advances·2026

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Tacrolimus is an established immunosuppressant widely used in organ transplantation.
  • It has also been developed and launched for treating atopic dermatitis in multiple countries.
  • Research has explored tacrolimus for rheumatoid arthritis and other autoimmune conditions.

Purpose of the Study:

  • To evaluate the development of tacrolimus for inflammatory bowel disease (IBD).

Main Methods:

  • Review of clinical trial data and regulatory submissions for tacrolimus in IBD.
  • Analysis of efficacy and safety data from Phase III trials.

Main Results:

  • Tacrolimus demonstrated potential in Phase III trials for IBD by March 2002.
  • The drug's development for IBD was progressing in Japan.

Conclusions:

  • Tacrolimus shows promise as a therapeutic option for inflammatory bowel disease.
  • Further evaluation is warranted to establish its role in IBD management.

Related Experiment Videos